Shuchi Gulati, M.D., M.Sc.
Assistant Professor, Division of Hematology and Oncology, Department of Internal Medicine
To see if Shuchi Gulati is accepting new patients, or for assistance finding a UC Davis doctor, please call 800-2-UCDAVIS (800-282-3284).
Locations and Contact
UC Davis Comprehensive Cancer Center
Hematology/Oncology Clinic
4501 X Street
Sacramento, CA 95817
Phone: 916-734-5959
Additional Numbers
Physician Referrals
Philosophy of Care
In my clinical practice, my goal is to provide "patient-centric", evidence based, high-quality care to my patients and thereby improve clinical outcomes as well as enhance patient experience through a coordinated approach. I focus on "shared decision making" as the epicenter of clinical care, where a patient's goals of care and beliefs are always taken into consideration. I primarily treat genitourinary cancers in adults and am passionate about making sure the latest clinical trials and treatment options are made available to everyone in an equitable manner. Patients with cancer are at a vulnerable point in their life and face immense psychosocial stressors. I engage with them, their families and not only strive to provide the best clinical care but also work diligently to make sure they receive the utmost compassion and respect from my team.
Clinical Interests
Dr. Gulati is a board-certified hematologist/ oncologist offering care for adult patients with genitourinary cancers, including kidney cancer, bladder cancer, prostate cancer and testicular cancer. Her research focuses on patient centered clinical trials with an emphasis on immunotherapy based combinations.
Research/Academic Interests
Dr. Gulati's research interest lies in identifying biomarkers of response and resistance to drugs in oncology care, specifically in genitourinary cancers. She studies pathways that make certain cancers more aggressive than others and works toward designing clinical trials to target these vulnerabilities. Her goal is to develop safe and effective therapeutic options to treat various cancers and improve outcomes of cancer patients.
Division
Hematology and Oncology
Center/Program Affiliation
Medical School
M.D., Dr. Rajendra Prasad Medical College, Himachal Pradesh, India 2005
Other School
M.S., Clinical and Translational Research, University of Cincinnati, Cincinnati OH 2020
Internship
Internal Medicine, Cleveland Clinic at Fairview Hospital, Cleveland OH 2009-2010
Residency
Internal Medicine, The Reading Hospital and Medical Center, West Reading PA 2010-2012
Fellowship
Hematology and Oncology, University of Cincinnati College of Medicine, Cincinnati OH 2015-2018
Fellowship
Internal Medicine Scholarly Training for Academic Research (IMSTAR), University of Cincinnati College of Medicine, Cincinnati OH 2019-2020
NCI K08 Mentored Career Development Award 2022-2027,
ASCO/ Conquer Cancer Foundation Career Development Award Recipient, 2021, 2022, 2023, 2024
KL2 Mentored Career Development Award Recipient, CCTST, University of Cincinnati, 2021, 2022
AACR/ ASCO Methods in Clinical and Translational Research Workshop, Vail, 2019
ASCO/ Conquer Cancer Foundation Merit Award, 2018
Pilot Award, University of Cincinnati Cancer Center, 2015
Leddon JL, Gulati S, Haque S, Allen C, Palackdharry S, Mathews M, Kurtzweil N, Riaz MK, Takiar V, Nagasaka M, Patil Y, Zender C, Tang A, Cervenka B, McGrath J, Korn WM, Hinrichs BH, Jandarov R, Harun N, Sukari A, Wise-Draper TM. Phase II Trial of Adjuvant Nivolumab Following Salvage Resection in Patients with Recurrent Squamous Cell Carcinoma of the Head and Neck. Clin Cancer Res. 2022 Aug 15;28(16):3464-3472. doi: 0.1158/1078-0432.CCR-21-4554. PMID:35653116.
Wise-Draper TM, Gulati S, Palackdharry S, Hinrichs BH, Worden FP, Old MO, Dunlap NE, Kaczmar JM, Patil Y, Riaz MK, Tang A, Mark J, Zender C, Gillenwater AM, Bell D, Kurtzweil N, Mathews M, Allen CL, Mierzwa ML, Casper K, Jandarov R, Medvedovic M, Lee JJ, Harun N, Takiar V, Gillison M. Phase II Clinical Trial of Neoadjuvant and Adjuvant Pembrolizumab in Resectable Local-Regionally Advanced Head and Neck Squamous Cell Carcinoma. Clin Cancer Res. 2022 Apr 1;28(7):1345-1352. doi:10.1158/1078-0432.CCR-21-3351. PMID:35338369.
Gulati S, Labaki C, Karachaliou GS, Choueiri TK, Zhang T. First-Line Treatments for Metastatic Clear Cell Renal Cell Carcinoma: An Ever-Enlarging Landscape. Oncologist. 2022 Mar 4;27(2):125-134. doi:10.1093/oncolo/oyab056. PMID:35641205.
Khaddam S, Gulati S. Spectrum of Presentations and Management Strategies in Renal Angiomyolipoma. J Kidney Cancer VHL. 2022 Jan 28;9(1):42-47. doi:10.15586/jkcvhl.v9i1.221. PMID:35127338.
Gulati S, Melissa P, Primo NL. BRCA1-Associated Protein 1 (BAP-1) as a Prognostic and Predictive Biomarker in Clear Cell Renal Cell Carcinoma: A Systematic Review. IOS Press. 2022 Jan 1;6(1):23–35. doi:10.3233/KCA-210006.
Gulati S, Vogelzang NJ. Biomarkers in renal cell carcinoma: Are we there yet? Asian J Urol. 2021 Oct;8(4):362-375. doi:10.1016/j.ajur.2021.05.013. Epub 2021 Jun 6. PMID:34765444.
Gulati S, Muddasani R, Gustavo Bergerot P, Pal SK. Systemic therapy and COVID19: Immunotherapy and chemotherapy. Urol Oncol. 2021 Apr;39(4):213-220. doi:10.1016/j.urolonc.2020.12.022. Epub 2020 Dec 26. PMID:33451934.
Czyzyk-Krzeska MF, Landero Figueroa JA, Gulati S, Cunningham JT, Meller J, ShamsaeI B, Vemuri B, Plas DR. Molecular and Metabolic Subtypes in Sporadic and Inherited Clear Cell Renal Cell Carcinoma. Genes (Basel). 2021 Mar 9;12(3):388. doi:10.3390/genes12030388. PMID:33803184.
Gulati S, Philip E, Salgia S, Pal SK. Evolving treatment paradigm in metastatic non clear cell renal cell carcinoma. Cancer Treat Res Commun. 2020 Mar 17;23:100172. doi:10.1016/j.ctarc.2020.100172. Epub ahead of print. PMID:32252014.
Gulati S, Desai J, Palackdharry SM, Morris JC, Zhu Z, Jandarov R, Riaz MK, Takiar V, Mierzwa M, Gutkind JS, Molinolo A, Desai PB, Sadraei NH, Wise-Draper TM. Phase 1 dose-finding study of metformin in combination with concurrent cisplatin and radiotherapy in patients with locally advanced head and neck squamous cell cancer. Cancer. 2020 Jan 15;126(2):354-362. doi:10.1002/cncr.32539. Epub 2019 Oct 18. PMID:31626727.